Drawing from the tumor immunoediting literature, we identified overexpression of the pro-survival protein BCL-2 as one potential mechanism of resistance—which can act to antagonize perforin/granzyme killing by sequestering truncated BH3-only domain members of the BCL-2 family (185). The gene discussed is BCL2; the disease is neoplasm.